Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Item

http://www.wikidata.org/entity/Q37521237

Q37521237

about

Appropriate revascularization in stable angina: lessons from the BARI 2D trial.Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease Current Indications for Stenting: Symptoms or Survival CME.

P2860

Q34696317-319A4EA8-ACBC-41A6-B4F6-D1A1D2414D21 Q40331861-DC1AE53C-3C5F-4201-A007-84AF354755F9 Q55315249-91601EF1-01EE-4B1A-9C83-21704A09DCD8

P2860

Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Item

http://www.wikidata.org/entity/Q37521237

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Frequency, predictors, and con ...... rug Evaluation (COURAGE) trial

@en

Frequency, predictors, and con ...... ug Evaluation (COURAGE) trial.

@nl

type

Item

label

Frequency, predictors, and con ...... rug Evaluation (COURAGE) trial

@en

Frequency, predictors, and con ...... ug Evaluation (COURAGE) trial.

@nl

prefLabel

Frequency, predictors, and con ...... rug Evaluation (COURAGE) trial

@en

Frequency, predictors, and con ...... ug Evaluation (COURAGE) trial.

@nl

P1476

Frequency, predictors, and con ...... rug Evaluation (COURAGE) trial

@en

P2093

Clinical Outcomes Utilizing Re ...... Investigators and Coordinators

http://www.w3.org/2001/XMLSchema#string

Daniel S Berman

http://www.w3.org/2001/XMLSchema#string

David J Cohen

http://www.w3.org/2001/XMLSchema#string

David J Maron

http://www.w3.org/2001/XMLSchema#string

G B John Mancini

http://www.w3.org/2001/XMLSchema#string

John A Spertus

http://www.w3.org/2001/XMLSchema#string

Leslee J Shaw

http://www.w3.org/2001/XMLSchema#string

Marcin Dada

http://www.w3.org/2001/XMLSchema#string

Merril Knudtson

http://www.w3.org/2001/XMLSchema#string

Mihaela Aslan

http://www.w3.org/2001/XMLSchema#string

P2860

Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, a

Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.

Optimal medical therapy with or without PCI for stable coronary disease.

Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.

2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to

From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events.

A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.

Diagnostic-therapeutic cascade revisited: coronary angiography, coronary artery bypass graft surgery, and percutaneous coronary intervention in the modern era

ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Societ

P304

409-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCOUTCOMES.113.000139

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Steven P Sedlis

Koon Teo

P577

2013-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23838107

http://www.w3.org/2001/XMLSchema#string

P921

revascularization

P932

3903667

http://www.w3.org/2001/XMLSchema#string

Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

about

P2860

P2860

Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932